-
131.发明公开SITE-SPECIFIC ATTACHMENT OF DRUGS OR OTHER AGENTS TO ENGINEERED ANTIBODIES WITH C-TERMINAL EXTENSIONS 有权SITE特异性药物或其他手段进行基因产生的抗体与C-末端延伸约束力
公开(公告)号：EP2185188A4
公开(公告)日：2011-07-13
申请号：EP08798164
申请日：2008-08-19
申请人： MEDAREX INC
发明人： LIU JIE , KING DAVID
IPC分类号： A61K39/00
CPC分类号： C07K16/2875 , A61K47/6803 , A61K47/6805 , A61K47/6819 , A61K47/6869 , A61K47/6889 , C07K16/3069 , C07K2317/21
-
公开(公告)号：EP1766093B1
公开(公告)日：2011-06-15
申请号：EP05857759.4
申请日：2005-02-04
发明人： AMBROSINO, Donna , BABCOCK, Gregory, J. , BROERING, Theresa , GRAZIANO, Robert , HERNANDEZ, Hector, Javier , LOWY, Israel , MANDELL, Robert , MOLRINE, Deborah , THOMAS, William, D. , ZHANG, Hui-fen
IPC分类号： C07K16/12 , A61K39/395 , A61P31/04
CPC分类号： C07K16/1282 , A61K39/08 , A61K48/00 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N15/86 , G01N33/56911 , G01N2333/33 , Y10S424/809 , A61K2300/00
摘要： Antibodies that specifically bind to toxins of C.difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
-
133.发明公开Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors 审中-公开人类中性抗OPGLAntikörperals selektive OPGL途径抑制剂
公开(公告)号：EP2314316A1
公开(公告)日：2011-04-27
申请号：EP10010381.1
申请日：2003-04-07
申请人： Amgen, Inc , Medarex, Inc.
发明人： Boyle, William J. , Medlock, Eugene , Sullivan, John K. , Elliott, Robin L. , Martin, Francis H. , Huang, Haichun
IPC分类号： A61K39/395 , C12N15/00 , C07K16/00
CPC分类号： C07K16/241 , A61K2039/505 , C07K16/2875 , C07K2317/21 , C07K2317/34 , C07K2317/56
摘要： Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
摘要翻译： 提供了与骨保护素配体（OPGL）相互作用的单克隆抗体和产生它们的杂交瘤。 还提供了通过向OPGL施用药学有效量的抗体来治疗骨质疏松症的方法。 进一步提供使用OPGL抗体检测样品中OPGL量的方法。
-
134.发明公开USE OF AN EFFICACY MARKER FOR OPTIMIZING THERAPEUTIC EFFICACY OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS 审中-公开有效性标记技术用于优化对肿瘤的抗人PD-1ANKÖRPERS的治疗功效
公开(公告)号：EP2307050A1
公开(公告)日：2011-04-13
申请号：EP09773195.4
申请日：2009-07-03
发明人： SHIBAYAMA, Shiro , YOSHIDA, Takao , HAYASHI, Tamon , HAYASHI, Akio , MURAI, Jun
IPC分类号： A61K39/395 , A61P35/00 , A61P35/02 , G01N33/53
CPC分类号： C07K16/2818 , A61K2039/505 , G01N2800/52
摘要： A purpose of the present invention is to provide a method capable of more effectively prescribing an anti-human PD-1 antibody for anti-cancer therapy, a method for estimating or optimizing therapeutic efficacy thereof, and further an efficacy marker that can be used in methods thereof. The present invention enables selection of the cancer patient in whom the therapeutic efficacy of the anti-human PD-1 antibody can be expected in future, by measuring the change which is more than a certain level of several kinds of efficacy markers in blood after administering the initial dose or doses of the anti-human PD-1 antibody compared to that prior to administering the initial dose, and provides a new prescription of the anti-human PD-1 antibody for anti-cancer therapy.
-
公开(公告)号：EP2277543A1
公开(公告)日：2011-01-26
申请号：EP10010884.4
申请日：2003-09-05
申请人： Amgen, Inc , Medarex, Inc.
发明人： Huang, Haichun , Varnum, Brian , Vezina, Chris , Witte, Alison , Qian, Xueming , Martin, Frank , Elliott, Gary
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1 R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
摘要翻译： 描述了与白细胞介素-1受体1型（IL-1R1）相互作用的抗体。 描述了通过向IL-1 R1施用药学有效量的抗体来治疗IL-1介导的疾病的方法。 描述了使用IL-1R1抗体检测样品中IL-1R1的量的方法。
-
136.发明公开ANTI-CLTA-4 ANTIBODIES WITH REDUCED BLOCKING OF BINDING OF CTLA-4 TO B7 AND USES THEREOF 审中-公开抗CTLA-4 CTLA-4的有约束力的减少封闭抗体B7及其用途
公开(公告)号：EP2240204A1
公开(公告)日：2010-10-20
申请号：EP09708994.0
申请日：2009-02-04
申请人： Medarex, Inc.
发明人： KORMAN, Alan , HALK, Edward, L. , WANG, Changyu , THUDIUM, Kent, B. , YANG, Lan , TOY, Kristopher
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2818 , A61K39/3955 , A61K2039/55516 , C07K2317/52 , C07K2317/565 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The present invention provides isolated monoclonal antibodies that bind to CTLA-4 and that are capable of increasing the response of T cells to antigenic stimulation in vivo yet the antibodies do not substantially block the binding of CTLA-4 to B7 ligands (e.g., B7-1 and B7-2) in vitro. Thus, the antibodies of the invention demonstrate that is it possible to separate the immunostimulatory function of anti-CTLA-4 antibodies from their ability to block the binding of B7 ligands. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for increasing the response of T cells to antigenic stimulation using the antibodies of the invention, including methods for treating cancer using the antibodies of the invention.
-
公开(公告)号：EP2213685A1
公开(公告)日：2010-08-04
申请号：EP10003365.3
申请日：2003-09-05
申请人： Amgen Inc. , Medarex, Inc.
发明人： Huang, Haichun , Varnum, Brian , Vezina, Chris , Witte, Alison , Qian, Xueming , Martin, Francis , Elliott, Gary
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
摘要翻译： 描述了与白细胞介素-1受体1型（IL-1R1）相互作用的抗体。 描述了通过向IL-1R1施用药学有效量的抗体来治疗IL-1介导的疾病的方法。 描述了使用IL-1R1抗体检测样品中IL-1R1的量的方法。
-
公开(公告)号：EP2178921A1
公开(公告)日：2010-04-28
申请号：EP08796249.4
申请日：2008-07-17
申请人： Medarex, Inc.
发明人： TERRETT, Jonathan, Alexander , LU, Li-sheng , HUANG, Haichun , YAO, Dapeng , PAN, Chin , LEBLANC, Heidi , SPROUL, Timothy , YAMANAKA, Mark
IPC分类号： C07K16/30
CPC分类号： C07K16/28 , A61K39/00 , C07K16/303 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/77 , C07K2317/92
摘要： The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.
-
139.发明公开Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics 有权为程序性死亡-1（PD-1）的人单克隆抗体，并用单独PD-1抗体或与其他免疫治疗剂组合治疗癌症的方法
公开(公告)号：EP2161336A1
公开(公告)日：2010-03-10
申请号：EP09013687.0
申请日：2006-05-02
发明人： Korman, Alan, J. , Srinivasan, Mohan , Wang, Changyu , Selby, Mark. J. , Chen, Bing , Cardarelli, Josephine M.
CPC分类号： A61K39/39558 , A61K39/00 , A61K39/3955 , A61K47/6849 , A61K51/10 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
-
140.发明公开TNF-ALPHA BLOCKER TREATMENT FOR ENTEROCOLITIS ASSOCIATED WITH IMMUNOSTIMULATORY THERAPEUTIC ANTIBODY THERAPY 审中-公开与相关的免疫刺激TNF-ALPHA-BLOCKER小肠结肠炎治疗的治疗性抗体治疗
公开(公告)号：EP1948214A4
公开(公告)日：2009-12-30
申请号：EP06827682
申请日：2006-11-08
IPC分类号： A61K38/16 , A61K39/395 , C07K14/00 , C07K16/00
CPC分类号： A61K39/39558 , A61K39/3955 , A61K2039/507 , C07K16/241 , C07K16/2818
-
-
-
-
-
-
-
-
-
搜索结果
218 条记录 (耗时 0.04 秒)
